Oracle has told customers that a hacker broke into a computer system and stole old client log-in credential, Bloomberg News reported on Wednesday, citing two people familiar with the matter.
Last month, an unidentified person began attempting to sell data online that was stolen from the cloud servers of Austin, Texas-based Oracle, according to the report.
It is the second cybersecurity breach that the software company has acknowledged to clients in the last month, the report said.
Oracle has told some clients that the Federal Bureau of Investigation and cybersecurity company CrowdStrike Holdings are investigating the incident, the report said, adding the attacker sought an extortion payment from the company.
The cloud computing company told customers that the data breach is separate from the hacking incident that it flagged to some healthcare customers last month, according to the report.
Oracle did not immediately respond to a Reuters request for comment, while a CrowdStrike spokesperson referred to the cloud company.
Oracle staff acknowledged to some clients this week that an attacker had gotten into a legacy environment, Bloomberg News report said.
The company informed customers that the system has not been in use for eight years and that the stolen client credentials therefore pose little risk, the report added.
The stolen data included Oracle customer log-in credentials from as recently as 2024, the report said.
Gov. Gavin Newsom stands behind his claim that “Big Oil” is responsible for California’s higher gas prices and vowed on April 1 to continue his fight against the industry. The pledge comes after new research put the blame on state regulations and policies for the high prices at the pump.
California’s Democratic leaders have come out strongly against the oil industry in recent years, saying the companies’ gouging was causing record-high gas prices.
“Gov. Newsom has done more than any other governor in recent history to tackle the challenge of rising gas prices—despite what the oil industry and its allies say,” a spokesman for Newsom told The Epoch Times in an email Tuesday.
A new study published March 16 by Michael Mische from the Marshall School of Business at the University of Southern California says the evidence contradicts Newsom. Mische’s research indicated California’s high gas prices were caused by the state’s regulations and policies.
“There is no economic data to support the allegation of price gouging,” Mische told The Epoch Times. “It just doesn’t exist.”
The professor also pushed back against Newsom’s claim that he was an industry ally.
“The data is the data,” Mische said.
Mische has been on the USC faculty since 1997, where he coordinates the business school’s management consulting undergraduate and graduate programs.
In March 2023, the governor signed a “windfall-profits penalty law” to target oil companies. The new law created a slew of regulations and extensive oversight for oil companies.
Newsom’s office said the governor saved Californians billions of dollars at the pump by signing the law.
The measure allows the governor’s appointed Energy Commission to fine and penalize oil companies if they earned profits beyond state-imposed limits.
California Gov. Gavin Newsom speaks in the Capitol rotunda in Sacramento on March 28, 2023. Courtesy of the Office of Gov. Gavin Newsom
The legislation also created a watchdog agency within the Energy Commission and appointed a Department of Justice prosecutor, Tai Milder, to oversee it.
“And with last year’s special session on gas price spikes, we have more tools on the way, including requiring oil refineries to maintain adequate supply to protect the state from supply-driven price spikes,” Newsom’s spokesman said Tuesday. In October, the governor signed a bill allowing the state to require that refiners keep a minimum inventory.
Study Show High Prices ‘Largely Self-inflicted’
According to the USC study, which included up to 50 years of data, California’s high gasoline prices and supply problems are “largely self-inflicted, and the result of directed policies and a litany of regulations, taxes, fees, and costs.”
“The economic evidence is abundant; California refiners have not engaged in widespread price gouging, profiteering, price manipulation, ‘unexplained residual prices’ or surcharges, magical or otherwise,” Mische wrote in the report.
Vehicles pass the Phillips 66 Los Angeles Refinery in Wilmington, Calif., on Nov. 28, 2022. Mario Tama/Getty Images
“The Golden State’s gasoline price dilemma is the result of the complex interactions of regulatory and political policies, and the subtleties of refinery operations and global crude oil prices and in-state centric supply and demand,” he added.
The state’s aggressive environmental policies are a major contributor, the report said. These include the state’s cap-and-trade charge for the industry that is passed down to the consumer. Environmental fees add about 51 cents per gallon of gas, according to the report. The state’s reporting and compliance costs are also high, which adds to the retail price of gasoline, including the state’s required special summer blend gasoline.
California also charges the highest excise tax in the nation, which along with local taxes and other program costs, increase prices at the pump, according to Mische.
Cargo shipping containers are seen adjacent to storage tanks at Marathon Petroleum's Los Angeles Refinery in Carson, Calif., on March 11, 2022. Reuters
Operating and refinery costs are also higher in California, he said.
The number of California refineries has also dropped by nearly 70 percent since 1984, from 43 to 13, Mische noted in the report.
The combination of regulations, taxes, and requirements placed on the oil and gas industry have driven up prices and taken a toll on the average working Californian who needs to drive to work, according to Mische.
“The issue is, we have Californians who are suffering,” Mische said. “They are feeling the squeeze and they’re going to feel more of the squeeze. We already have the highest cost of living in the United States. This just adds more burden onto the back of the consumer, and we can fix it.”
Vehicles pass a gas station in Rosemead, Calif., on Sept. 23, 2024. Frederic J. Brown/AFP
California is the second largest consumer of petroleum in the United States but produces less than 3 percent of the nation’s supply, the study found.
To meet the needs of drivers, utilities, and industry, the state is highly dependent on oil imports. California’s imports have increased significantly from Saudi Arabia and Iraq, and other petrostates such as Brazil, Guyana, and Ecuador, according to the report.
Nevada gas prices also hinge on California refineries, as the Silver State’s retailers get most of their supply from the state next door.
The study’s results were no surprise to industry and political leaders who are critics of Newsom’s stance on the industry.
Catherine Reheis-Boyd, director of the Western Petroleum Association in Los Angeles, said the study backs up what the association has said for years.
“It’s no secret that California has gotten in its own way when it comes to high [gas prices] and supply challenges,” Reheis-Boyd posted on X March 20.
Rigs extract oil in Culver City, Calif., on May 16, 2008. Gabriel Bouys/AFP via Getty Images
State Senate Republican Leader Brian Jones, of Santee, said 83 percent of California voters agree that gas prices are too high.
Jones told The Epoch Times in an email, “Despite knowing what’s driving costs up, Democrats refuse to fix their mistakes. In fact, they continue to double down on their war against our wallets and raise prices at the pump.”
California had the highest gas prices in the nation Tuesday, with an average of $4.85 per gallon, according to the American Automobile Association (AAA).
The national average was $3.20, AAA reported.
The second most costly gas could be found in Hawaii, where consumers paid an average of $4.52, AAA reported.
“We now know the reason our prices are $1.65 higher than the national average,” Jones added.
“Enough with the political grandstanding and games. It’s time to get to work and finally lower these prices.”
Another report, published March 18 by the Los Angeles Economic Development Corporation (LAEDC), titled “Oil and Gas in California,” shows California’s oil and gas industry is essential to the state’s economy.
“Despite facing significant challenges, including regulatory pressures, market fluctuations, and global geopolitical tensions, the industry has continued to provide critical economic, employment, and fiscal benefit across the state,” the report stated.
The data used in the report was from 2022—the same year that the governor vowed to punish “Big Oil” for allegedly “price gouging.”
It looks as though government funding for mRNA technology is on a short leash...
Take, for example, a promising mRNA vaccine for pancreatic cancer, developed by Memorial Sloan Kettering, that showed encouraging early results: in some patients, immune responses lasted up to four years and appeared to reduce recurrence.
It is being overshadowed by new concerns about federal support for mRNA research, according to a new op-ed by science commentator Anjana Ahuja in the Financial Times.
According to Nature, NIH officials are informally advising scientists to remove references to mRNA from grant applications, and a spreadsheet tracking 130 related projects has raised fears of funding cuts.
NIH claims it's simply reviewing what mRNA work it currently funds, but the lack of clarity has sparked unease—especially given the agency’s massive $47 billion research budget.
Drew Weissman, the Nobel-winning scientist behind mRNA vaccine breakthroughs, warned that cutting NIH support for mRNA research would stall medical progress and harm U.S. science. Even the threat of funding cuts creates fear and instability, especially for young researchers who may now look abroad for more secure opportunities.
To which we reply: if mRNA vaccines have a safe solution, the free market will eventually allow them to flourish...
But the Financial Times piece says that concerns have intensified with Robert F. Kennedy Jr. leading Health and Human Services, and reports that mRNA projects are being scrutinized or sidelined politically.
One early study using personalized mRNA cancer vaccines is already yielding hopeful results and has launched a broader global trial, according to the op-ed.
Scientists argue that pulling support now could derail life-saving innovation. As history shows, today’s medical breakthroughs rest on decades of consistent public research investment — a pipeline that can’t survive in a climate of political interference.
A generative artificial intelligence (Gen-AI)–powered therapy chatbot known as Therabot was associated with significant reductions in several mental health conditions, including major depressive disorder (MDD).
Developed by members of the investigative team, Therabot is a mobile app that allows users to interact with a digital presence they understand is not a real person. Using user prompts and conversation history, the chatbot delivers tailored dialogue, including empathetic responses and targeted questions.
In a randomized control trial (RCT) of more than 200 US participants, those who received the chatbot intervention for 4 weeks had significantly greater symptom reductions in MDD, generalized anxiety disorder (GAD), and feeding and eating disorders (EDs) than their peers who did not receive access to the app (waitlist control group) — meeting its primary outcomes.
On average, engagement with the app lasted more than 6 hours and was rated highly by patients.
Nicholas Jacobson, PhD
“The effect sizes weren’t just significant, they were huge and clinically meaningful — and mirrored what you’d see in a gold-standard dose of evidence-based treatment delivered by humans over a longer period of time,” senior study author Nicholas Jacobson, PhD, associate professor of biomedical data science and psychiatry at Dartmouth College's Geisel School of Medicine, Hanover, New Hampshire, told Medscape Medical News.
Therabot is “an expert-fine-tuned” Gen-AI–powered chatbot created specifically for mental health treatment, with experts writing therapist-patient dialogues based on cognitive-behavioral therapy.
Jacobson, who is also a director at Dartmouth’s Center for Technology and Behavioral Health, Lebanon, New Hampshire, noted that the investigators started developing the app in 2019. It now has more than 100,000 human hours put into it through software creation and refinement.
“Therabot is designed to augment and enhance conventional mental health treatment services by delivering personalized, evidenced-based mental health interventions at scale,” the researchers wrote.
Jacobson noted that other digital interventions created for the mental health space are often more structured and not adaptive or personalized, leading to lower engagement and large dropout rates. In addition, safety and efficacy have not been well established for many of these systems, he said.
What sets this app apart is its long development history that it provides diligent oversight, and its “personalized dynamic feedback” that responds much like a human therapist, he said.
“We designed our own dataset written out with transcripts on what would be a gold-standard response to every different type of query you can imagine related to these conditions and also comorbidities,” said Jacobson.
A Starting Place
The researchers enrolled 210 adults (59.5% women; mean age, 33.9 years) with severe symptoms of MDD or GAD or at high risk for feeding and EDs. All were randomly assigned to interact daily with the chatbot intervention for 4 weeks (n = 106) or to receive no app access (waitlist, n = 104).
Jacobson noted the investigators wanted to concentrate on these three specific conditions because they are among the most common mental disorders.
“We wanted to have a starting place” that could be expanded upon in the future, including the possibility of other conditions, he added.
Daily prompts to interact with Therabot occurred throughout the 4-week treatment period. The prompts stopped after that, but the group could still access the app during the following 4-week postintervention phase.
Although the waitlist group was not given access to the app during the study period, they could gain access at the end of the follow-up at 8 weeks.
The co-primary outcomes were changes in symptoms from baseline to 4 weeks and to 8 weeks. Measures included the Patient Health Questionnaire 9, the GAD Questionnaire for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and the Weight Concerns Scale within the Stanford-Washington University Eating Disorder.
User engagement, acceptability, and “therapeutic alliance” were all secondary outcomes. The investigators defined the latter as “the collaborative patient and therapist relationship” as measured on the Working Alliance Inventory-Short Revised (WAI-SR). Other measures included a patient satisfaction survey and the number of messages sent to the app.
Effective, Satisfying Results
Results showed that compared with the waitlist group, the chatbot group had significantly greater reductions in MDD symptoms at 4 weeks (mean change, −2.63 vs −6.13; P < .001) and 8 weeks (mean change, −4.22 vs −7.93; P < .001).
Similarly, the chatbot group also had greater reductions in symptoms of GAD at 4 weeks (mean change, −0.13 vs −2.32; P = .001) and 8 weeks (mean change, −1.11 vs −3.18; P = .003) and in symptoms of EDs at both timepoints (mean changes, −1.66 vs −9.83; P = .008 and −3.7 vs −10.23; P = .03, respectively).
These improvements “were comparable to what is reported for traditional outpatient therapy, suggesting this AI-assisted approach may offer clinically meaningful benefits,” Jacobson said in a release.
Based on WAI-SR scores, the participants also, on average, “reported a therapeutic alliance comparable to norms reported in an outpatient psychotherapy sample,” the investigators reported.
Overall satisfaction with the app received an average of 5.3 on a scale, where 7 was considered highest. In addition, the app received a 6.4 for ease of use, a 5.6 for being intuitive, a 5.4 for feeling better after a session, and a 4.9 for the app being rated as “similar to a real therapist.”
The mean number of participant messages sent was 260, and the mean total amount of app interaction was 6.2 hours.
The investigators noted that they and trained clinicians examined all responses from the app, and if any inappropriate responses were given, they contacted the patient directly.
At study’s end, staff interventions were required 15 times because of safety concerns, such as after participants expressed suicidal ideation, and 13 times because of inappropriate app responses, such as providing medical advice.
First Study of Its Kind
“This is the first RCT demonstrating the effectiveness of a fully Gen-AI therapy chatbot for treating clinical-level mental health symptoms,” the investigators noted.
They credited three factors for the chatbot’s success — it was “rooted” in evidence-based psychotherapies for the three conditions treated, its unrestricted/anytime access, and “unlike existing chatbots for mental health treatment, Therabot was powered by Gen-AI, allowing for natural, highly personalized, open-ended dialogue.”
Still, lead study author Michael Heinz, MD, assistant professor of psychiatry at Dartmouth and an attending psychiatrist at Dartmouth Hitchcock Medical Center, did voice some cautions.
Michael Heinz, MD
“The feature that allows AI to be so effective is also what confers its risk — patients can say anything to it and it can say anything back,” he said in the release. That’s why the various systems being developed need rigorous safety and efficacy benchmarks, as well as supervision/involvement of mental health experts, he said.
“I don’t necessarily think they need to be used with a prescription model. I just think we need human experts in the loop until we have a good understanding of their safety and efficacy,” Heinz told Medscape Medical News.
He added that human interventions weren’t often needed with Therabot, “but that is always a risk with generative AI and our study team was ready.”
So what’s next? Although Therabot isn’t available to patients and/or clinicians currently, and remains only in the research space, the goal is to make it widely available in the next few years, Jacobson said.
“But we want to proceed judiciously. A lot of our work is to ultimately scale it, but these models carry greater risk — in part because of their flexibility. So we want to have greater oversight and further trials before we open it up,” Jacobson added, noting that could eventually include head-to-head comparisons with live providers.
More Question Than Answers
Commenting for Medscape Medical News, Paul Appelbaum, MD, practicing psychiatrist and professor of psychiatry at Columbia University, New York City, described the study as interesting, with promising results.
Paul Appelbaum, MD
However, it was also a single study that “raises more questions than it answers about the use of AI-driven chatbots,” said Appelbaum, who was not involved with the research.
He noted that there may have been a “novelty effect” because of the intervention’s relatively short duration, and that selection bias, which the investigators mention in their paper, could have resulted in an overestimation of the effectiveness of the digital intervention for the three conditions studied.
“People who are willing to participate in a study of a chatbot may be predisposed to view technological approaches as appealing. So whether a random sample of the general population would have the same response is an open question,” Appelbaum said.
He also pointed out that the control group didn’t receive anything, and wondered how a more active control intervention would have compared to the chatbot. “Is the difference between the two groups a function of the effect from the chatbot as opposed to the negative effect of being told ‘you’re just on a waiting list?’”
Appelbaum also noted the investigators’ ongoing supervision of AI to ensure patient safety.
“I think that’s a very important caveat. There’s a temptation to read this study as indicating that we can just turn patients over to chatbots and they’ll take care of it — but that is not what happened,” he said.
Disclosures and conflicts of interest of the investigators are fully listed in the original article. Appelbaum reported no relevant financial relationships.
Preliminary results from a new study showed that the risk for sudden cardiac death (SCD) was more than twice as high in individuals who used antidepressants for 6 or more years compared with that in those not taking the medications.
While the findings suggest a possible association between long-term antidepressant use and SCD, researchers caution that the results do not imply these medications are inherently dangerous or should be discontinued.
Jasmin Mujkanovic, MD
“I hope doctors don’t think they need to discontinue this treatment because it might pose a risk of sudden cardiac death,” study investigator Jasmin Mujkanovic, MD, PhD student, Copenhagen University Hospital, Copenhagen, Denmark, told Medscape Medical News.
Mujkanovic emphasized that depression itself is a known risk factor for SCD and that effective treatment can improve quality of life and support healthier lifestyle choices, which may in turn help reduce heart-related risks.
The findings were presented on March 30 at the European Heart Rhythm Association 2025, a scientific congress of the European Society of Cardiology.
Filling a Research Gap
Previous research has shown a link between long-term antidepressant use and poor cardiac health. Antipsychotics have also been tied to an increase risk for cardiovascular disease in older adults with dementia.
While earlier studies suggested that patients with depressive disorders have an increased risk for SCD, the effect of antidepressant exposure on SCD risk was unclear.
Researchers reviewed all death certificates and autopsy reports from 2010 among the 4.3 million residents of Denmark aged 18-90 years. The year 2010 was chosen because some of Mujkanovic’s colleagues had already assessed every death certificate for that year and entered pertinent information into a database.
The researchers defined antidepressant exposure as having filled at least two prescriptions for the medication within a single year during the 12 years leading up to 2010, the start of the follow-up period. Exposure was categorized as either 1-5 years or 6 years or more.
Based on available data, deaths were categorized as SCD or non-SCD. There were 6002 deaths due to SCD, which included 1981 in the antidepressant cohort and 4021 in the unexposed population.
Investigators found that the risk for SCD was significantly higher in individuals exposed to antidepressants than in the general population across all age groups — except those aged 18-29 years, where the association was not statistically significant. Mujkanovic suggested that younger patients may not have used antidepressants long enough to be classified as having prolonged exposure.
After adjusting for age, sex, and comorbidities, including ischemic heart disease, chronic obstructive pulmonary disease, diabetes and arrhythmias, the risk for SCD was 56% higher in those with 1-5 years of exposure to antidepressants (hazard ratio [HR], 1.56; P < .001) and more than double for those with 6 or more years of exposure (HR, 2.17; P < .001).
Risk by Age, Duration
The risk for SCD among individuals taking antidepressants, compared with the unexposed general population, varied slightly across age groups. However, among those aged 40-79 years, the incidence of SCD was significantly higher in individuals with 6 or more years of antidepressant use than in those with 1-5 years of exposure.
When comparing longer to shorter durations of antidepressant use, the differences in risk were significant in the following age groups: 40-49 years (incidence rate ratio [IRR], 1.7; P = .03), 50-59 years (IRR, 2.0; P < .001), and 60-69 years (IRR, 1.4; P < .001).
The differences in risk between antidepressant exposure durations were not statistically significant among the younger participants (age, 18-39 years) and the oldest group (age, 80-90 years).
Due to the study’s design, it’s challenging to determine whether the increased risk for SCD is linked to the underlying condition of depression or to the antidepressant medications themselves, Mujkanovic said. However, if the medications do contribute to the risk, it may be because some can alter the heart’s electrical activity, he noted.
Mujkanovic also pointed out that certain antidepressants are associated with significant weight gain and QT interval prolongation, which can lead to metabolic syndrome — a known risk factor for atherosclerosis.
“It’s like a chain reaction — atherosclerosis is a known risk factor for ischemic heart disease, and ischemic heart disease increases the risk for myocardial infarction, which increases the risks for cardiac death,” Mujkanovic said.
The study did not distinguish between different classes of antidepressants — such as selective serotonin reuptake inhibitors and tricyclics — and participants may have switched between classes during the study period.
It also did not analyze men and women separately, though Mujkanovic expressed interest in exploring sex-specific differences in future research.
Other Risk Factors
Several experts weighed in on the findings in a statement from the UK-based independent nonprofit Science Media Centre (SMC).
Paul Keedwell, MB, PhD, consultant psychiatrist and fellow of the Royal College of Psychiatrists in London, the United Kingdom, agreed with the investigators’ caution against discontinuing antidepressants based on the study’s findings.
“The results should be treated with caution because the study was unable to separate the risks of antidepressant treatment from the risk of having depression per se,” Keedwell said.
Depression is linked to a 60% higher risk for heart disease, including SCD, a 50%-90% increased risk for life-threatening arrhythmias, and approximately double the risk for heart attack, Keedwell noted.
He added that individuals with depression tend to die earlier than those in the general population — with men dying up to 14 years earlier and women dying up to 10 years earlier.
While suicide contributes to this excess mortality, Keedwell emphasized that the leading cause is poor physical health, likely driven by an unhealthy lifestyle.
“More research is needed to directly compare the life expectancy in treated and untreated depression, but as things stand, the weight of evidence supports the conclusion that the risk of early death is much higher when depression is left untreated than when it is treated,” he said. “Therefore, people should not stop their antidepressant treatment based on this study.”
Also commenting for the SMC, Charles Pearman, MB, PhD, consultant cardiologist and electrophysiologist at Manchester University NHS Foundation Trust, noted that previous studies have identified a link between antipsychotic use and an increased risk for SCD.
He added that antidepressants may not directly cause SCD but could instead serve as markers for other underlying health issues or risk factors — such as obesity, hypertension, diabetes, smoking, or physical inactivity.
“The investigators tried to account for this possibility, but it is unclear which risk factors they considered,” Pearman said.
Pearman emphasized that the overall risk remains low and, like the study authors, advised against patients abruptly discontinuing their antidepressant treatment. Overall, while there was an increased risk from taking antidepressants, the risk remains small, he noted.
“People who are concerned about their risks should speak to their GP [general practitioner] rather than stopping their medicines abruptly,” he said.
The study received no external funding. Mujkanovic and Keedwell reported n o related conflicts of interest. Pearman disclosed no relevant conflicts.
Mayor Eric Adams:Thank you so much and you know the other day I was at a town hall where we were listening to a group of residents and they talked about some of the concerns that they had in the city. At the end of the town hall there was a gentleman sitting in the back with his daughter and he raised his hand and I said before we leave let's hear what his question was. And he stood up and stated that he has four children and he lived in a homeless shelter and he was able to get one of our vouchers, our thefts vouchers, and he was able to move out of the shelter and find an apartment. But he lost his job. He was a security officer at one of the drug stores and because of the constant theft, the store closed down and he lost his job and he was unable to provide for his family.
We were able to get him a voucher to get in housing and after the town hall we were able to identify a new job for him. But what about that store? What about the other employees? What about the grandmother that had to take the bus to go to another store outside of our community and had to pay [for] the transportation on an already strained budget? What about the clerks and those cashiers who work there and now had to find a new employment to be able to provide for their family? What about that storefront that now remains empty because of it?
So I challenge people who tell us that retail theft is a victimless crime, that there are no victims. They are victims. They are real victims and it impacts on many layers of our desire to continue the prosperity that this city has to offer. That is why when we became mayor and many of you came to us and put this on our radar, we did not sit back and dismiss it in an arrogant sense as though it's not a major issue. It is a major issue.
And coming together we decreased retail theft about 8.2 percent but that is not enough. And we called on our lawmakers to say how do you have 575 people who are arrested 7,500 times and we're not adjusting the laws to fit that. You cannot solve problems in a sterilized environment of a legislative chamber when on the streets of our cities you're seeing these problems continue to escalate. That is the real crisis we face. Too many people don't go out and hear directly from you on how we fix the issues we are facing. That is not who I am as a mayor.
Generals don't send the troops into battle, they lead them into battle and they fight with them. So I stop in your stores and your restaurants and ask what are the real problems that we are facing so we can come up with real solutions. We brought technology together. We looked at other ways of how we can answer the problems in [a] real way. There's no greater indictment on our system than when you have to lock up every item and push a button for someone to come and give you what you need.
Those are indicators of surrenders and we don't surrender. We fight back. We solve the problem and we come to real conclusions together. That's what we must do. And this city is coming back, bigger and better than ever. And those with the foolish assumption that this is a city of chaos, that is a lie. You can't find restaurant reservations anymore in this city because people are out again and just go walk down Times Square and [see] everyone that's trying to come to New York, the fourth largest tourist production in the city's history.
People are again excited about this city. And at the cornerstone of that are your shops, your stores, your supermarkets. We need to make sure that you can thrive and that people don't normalize walking in, taking whatever product they want and believing we abandon the right for you to provide a service to the people of this city. And so I thank you for what we started and we have more to finish, but you have my commitment and dedication that we are going to do all that's possible to not alleviate retail theft, but to eradicate retail theft. Thank you very much.
NeuroPace (NPCE) announced a strategic refocusing of its product portfolio, terminating its SEEG products distribution relationship with DIXI Medical in Q4 2025. The company will maintain its focus on its core RNS System product line.
The company reaffirmed its 2025 revenue guidance and long-range plan expectations, including:20%+ revenue CAGR Cash flow breakeven target by end of 2027 Gross margin improvement (RNS System >78% vs SEEG ~50%)
Key growth initiatives for 2026 include:Project CARE site of service expansion Indication expansion into drug-resistant idiopathic generalized epilepsy Expansion into pediatric focal epilepsy Launch of AI-enabled software products
